Pfizer has agreed to buy ReViral, a privately held business based in the UK, for as much as $525 million in an attempt to gain access to experimental drugs to treat a respiratory virus.

The US pharmaceutical giant said the deal was designed to strengthen its pipeline of treatments. It is its second acquisition in less than six months after the $6.7 billion takeover of Arena Pharmaceuticals in December.

ReViral, founded in 2011, is focused on discovering and developing antiviral therapeutics that target respiratory syncytial virus (RSV), which causes cold-like symptoms. It is a cause of pneumonia in young children and the elderly. It has offices in Stevenage, Hertfordshire, and in Durham, North Carolina.

Albert Bourla, chairman and chief executive of Pfizer, said: â€œWe have